Ross Bundy is a pioneering biotechnology leader driving innovation in biosensor technology and genome editing optimization. As the CEO of CRISPR QC and co-founder of Cardea Bio Inc., he has been instrumental in developing platforms that enable real-time biological insights through the "Internet of Biology." With expertise in business development, financial strategy, and operational management, Bundy has successfully scaled multiple companies and forged key industry partnerships. His visionary leadership and strategic execution continue to shape the future of biotechnology, advancing diagnostics, therapeutics, and bioinformatics with cutting-edge solutions.

Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.

Thrilled to share my professional biography, which captures the arc of my 30+ year journey across life sciences, innovation, strategy, and global health. I’ve had the honor of collaborating with visionary leaders and organizations to unlock transformative value at the intersection of science, business, and impact.

Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.

Jennifer T. Feldman, MBA, HTL (ASCP), QIHC, is a visionary healthcare business development leader with over 23 years of experience in oncology diagnostics, medical devices, and biotechnology. She has a proven track record of driving strategic partnerships, advancing innovative technologies, and optimizing commercial success in the healthcare industry. Jennifer’s expertise spans clinical pathology, research-use-only applications, and companion diagnostics, making her a key player in transforming patient care. With an MBA in International Business and certifications in histotechnology and immunohistochemistry, she seamlessly blends technical proficiency with business acumen. A sought-after speaker and industry expert, Jennifer is passionate about leveraging her knowledge and leadership to foster innovation, improve healthcare outcomes, and contribute to the future of medical advancements.

After 25+ years working at the intersection of science and strategy in cell and gene therapy, I’m excited to share a comprehensive look into my professional journey—from hands-on scientific innovation to leadership across CDMOs, biotech, and academic institutions. My passion lies in building high-impact teams, developing therapies that matter, and bridging ideas to execution. Here is my biography.

Klodjan Stafa is a visionary biomedical research leader with a proven track record of advancing innovation at the intersection of dermatology, neuroscience, and molecular biology. With over 15 years of experience spanning academia and industry, he leads high-impact R&D initiatives that drive product development and business growth on a global scale. Known for his ability to cultivate top-performing teams and foster strategic partnerships, Klodjan combines scientific depth with business acumen to deliver breakthrough solutions. His work has contributed to multi-million dollar product launches, influential publications, and patented technologies, positioning him as a trusted voice in translational science and a catalyst for meaningful change in biomedical research.

Brian Dakin, PMP, CIPM, is a seasoned leader in project management, data privacy, and technology solutions within the life sciences industry. As the Principal of Rhombus Consulting, he has driven strategic initiatives that enhance operational efficiency, regulatory compliance, and data governance for pharmaceutical and biotechnology organizations. In his role as President and Head of Operations for a trusted third-party entity, he has led efforts in patient de-identification, achieving HIPAA and SOC2 Type 2 compliance while increasing revenue and profitability. A thought leader and member of the Forbes Coaches Council, Brian also developed **On The Ball Theory**, a framework designed to help individuals unlock their potential and achieve meaningful personal and professional goals. His extensive experience, combined with his commitment to innovation and mentorship, has positioned him as an influential figure in both corporate leadership and personal development.

I’m excited to share my professional journey in agricultural sales, market development, and strategic leadership. With over 40 years of experience in the animal agriculture industry, I have had the privilege of working with top organizations, expanding markets, and introducing innovative solutions to drive growth. As I seek new opportunities to contribute through board service, I look forward to collaborating with like-minded professionals to support the agricultural sector's continued evolution. Here is my biography.

As a physician-scientist and biotech executive, I have dedicated my career to bridging the gap between groundbreaking medical research and commercial success. From securing multimillion-dollar funding to leading strategic M&A deals, my passion lies in driving healthcare innovation that delivers real-world impact. Here is my biography.

Eric Trac is a visionary healthcare investor and biopharmaceutical strategist with a unique blend of medical expertise and financial acumen, driving transformative growth in the healthcare sector. As a Senior Analyst & Director at Sarissa Capital Management, he leads activist investment strategies, evaluates public and private market opportunities, and serves as a board director at Lyndra Therapeutics. With a background in venture capital at Vida Ventures and Vivo Capital, he has played a pivotal role in high-impact transactions, including Bayer’s $4 billion acquisition of AskBio and Centessa Pharmaceuticals’ $250 million Series A. Trac’s deep scientific foundation stems from his MD and MBA from Stanford University and his research in biotechnology at MIT, where he graduated in the top 8% of his class. Recognized as one of *Business Insider’s* “14 Most Impressive Students at MIT,” he continues to leverage his expertise in medicine and finance to drive innovation, maximize shareholder value, and advance the future of biopharmaceuticals.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Matthew Smollin, PharmD, is an accomplished leader in medical affairs and clinical innovation with over 15 years of clinical experience and a decade of industry expertise spanning clinical research, regulatory strategy, and team leadership. As Vice President of Medical Affairs at Karius, Inc., he directs medical and scientific strategies, guiding breakthrough advancements in molecular diagnostics while navigating complex FDA and Medicare regulatory processes. Throughout his career, he has successfully built and managed high-performing teams, fostered strong relationships with key opinion leaders, and played a pivotal role in clinical trial design, publication strategy, and scientific engagement. A respected speaker and thought leader, Dr. Smollin’s expertise in infectious disease diagnostics and next-generation sequencing has shaped industry best practices and advanced clinical innovation. His dedication to scientific excellence, strategic vision, and ability to translate complex medical insights into impactful solutions make him a driving force in the evolution of precision medicine and diagnostic technologies.

Excited to share my professional executive biography! With over 20 years of experience in biotech program management, drug development, and regulatory strategy, I have had the privilege of leading cross-functional teams, guiding early-stage startups, and ensuring successful clinical execution. If you're looking for strategic leadership, operational excellence, and industry expertise, I’d love to connect and explore opportunities to collaborate.

Ian Rickard is an accomplished executive with a proven track record of driving business growth, technological innovation, and market expansion in the biofuels, filtration, and beverage industries. As the General Manager of North America at Separator Technology Solutions US Inc., he leads strategic development and sales initiatives across the U.S. and Canada, advancing the company’s presence in multiple sectors. With a background in biotechnology and over two decades of experience, Ian has played a pivotal role in launching industry-first technologies, expanding market share, and fostering business transformation. His leadership, technical expertise, and strategic vision continue to shape the future of advanced filtration and separation solutions.

Excited to share my professional journey in NGS cancer diagnostics, biotech, and healthcare innovation! With over 20 years of experience spanning product management, AI-driven automation, clinical trials, and regulatory compliance, I have led multi-billion-dollar product launches and driven transformative advancements in precision medicine and oncology. My expertise in agile methodologies, strategic planning, and cross-functional leadership has enabled me to bridge science and business for impactful solutions. Here is my biography.